A third way for drug addiction policy in Canada title=
A third way for drug addiction policy in Canada

PJ2 Stock Price and Chart GETTEX:PJ2 TradingView [Video]

Canadian Economy and Markets

Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.

New tools or new competitors? The future of competition law in Canada